Background: The use of new technologies boosted Industry 4.0, making processes more sophisticated and considering the interaction between physical production systems and workers. But these new technologies also intervene in the worker's quality of life (QoL), that is, we need to know if the industry of the future is changing the scenario of the present.
Objective: This study aims to identify trends in study topics related to QoL in Industry 4.0.
Methods: A bibliometric mapping analysis was performed without temporal delimitation in the Scopus, Web of Science and PubMed databases.
Results: The results show that: (i) the publications most aligned with the theme are from 2016 onwards; (ii) the greatest growth in publications on the subject occurred between the years 2019, 2020 and 2021; (iii) the Journal Sustainability was the most relevant journal on the subject in recent years; (iv) Turkey stood out as the most cited country in the field of study; (v) there are collaboration networks between authors in several countries, including Denmark, Italy and Poland; (vi) with the analysis of the thematic map, it is possible to identify which themes are the motor, specialized, emerging, missing, or basic from the research field and; (vii) the sub-themes that appeared the most in the surveys were work environment, impact of Industry 4.0, robots, health and well-being, digitalization and job satisfaction.
Conclusion: In addition to being a relevant source of information, where readers find future thematic trends in the field of research, it is hoped that the contributions of this study will provide insights for researchers, academics and society in general.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3233/WOR-220637 | DOI Listing |
ACR Open Rheumatol
January 2025
Duke University and Duke Clinical Research Institute, Durham, North Carolina.
Objective: The objective of this study was to evaluate the preliminary effectiveness of an electronic pill bottle with automated reminders on hydroxychloroquine (HCQ) adherence in children with pediatric systemic lupus erythematosus (pSLE).
Methods: This was a self-controlled, open label, direct-to-family pilot trial. Children with pSLE treated with HCQ were recruited from the Childhood Arthritis and Rheumatology Research Alliance Registry.
Eur Heart J Digit Health
January 2025
Department of Cardiovascular Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA.
Aims: Gender-affirming hormone therapy (GAHT) is used by some transgender individuals (TG), who comprise 1.4% of US population. However, the effects of GAHT on electrocardiogram (ECG) remain unknown.
View Article and Find Full Text PDFHSS J
February 2025
Division of Orthopaedic Surgery, McMaster University, Hamilton, ON, Canada.
Background: The study of value in orthopedic surgery aims to maximize health outcomes gained per unit cost through various health economic tools but is fragmented across various subspecialties and geographies. Therefore, it is difficult to ascertain whether this research methodology is being used to its full potential across all orthopedic subspecialties and geographies.
Purpose: We sought to assess the distribution of prior health economics literature in orthopedic surgery across subspecialties and geographies.
Background And Aims: Hematopoietic stem cell transplantation (HSCT) is a key therapeutic approach for pediatric patients with hematologic and non-hematologic disorders. However, post-transplant pulmonary complications remain a significant cause of morbidity and mortality. Pulmonary Function Tests (PFTs) are essential for the early detection of pulmonary dysfunction, yet their application in pediatric HSCT recipients has yielded inconsistent results.
View Article and Find Full Text PDFBackground And Aims: Non-Alcoholic Steatohepatitis (NASH), a severe form of Non-Alcoholic Fatty Liver Disease (NAFLD), is characterized by inflammation and fibrosis in the liver, often progressing to cirrhosis and hepatocellular carcinoma. Despite its rising prevalence and significant disease burden, effective pharmacological treatments have been limited to lifestyle modifications and surgical interventions. Recently, resmetirom, a thyroid hormone receptor-β agonist, received FDA approval for treating NASH, offering new hope to patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!